Status:
NOT_YET_RECRUITING
Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Familial Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Background: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of interstitial lung disease. Between 2% and 20% of patients with IPF have a family history of the disease, which is...
Eligibility Criteria
Inclusion
- Criteria for PATIENTS:
- patients aged ≥18 years when signing the informed consent
- diagnosis of IPF based on 2022 ATS/ERS/JRS/ALAT Guidelines as confirmed by the investigator based on chest HRCT scan and if available surgical lung biopsy
- diagnosis of FPF defined as the presence of fibrotic ILD in at least two members of the same biological family
- at least one 1st degree relative \>40 years of age.
Exclusion
- patients with Interstitial Lung Diseases other than Idiopathic Pulmonary Fibrosis, including but not limited to patients with granulomatous lung disease, autoimmune/collagen vascular disease associated interstitial lung disease, and drug induced interstitial lung disease
- unwilling or unable to sign informed consent
- Criteria for FIRST DEGREE BIOLOGICAL RELATIVES:
- Inclusion Criteria:
- a. subjects aged ≥40 years
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06521125
Start Date
September 1 2024
End Date
September 1 2026
Last Update
July 25 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.